https://scholars.lib.ntu.edu.tw/handle/123456789/633126
標題: | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer | 作者: | Yoshino, T Cervantes, A Bando, H Martinelli, E Oki, E Xu, R-H Mulansari, N A Govind Babu, K Lee, M A Tan, C K Cornelio, G Chong, D Q Chen, L-T Tanasanvimon, S Prasongsook, N KUN-HUEI YEH Chua, C Sacdalan, M D Sow Jenson, W J Kim, S T Chacko, R T Syaiful, R A Zhang, S Z Curigliano, G Mishima, S Nakamura, Y Ebi, H Sunakawa, Y Takahashi, M Baba, E Peters, S Ishioka, C Pentheroudakis, G |
關鍵字: | ESMO; Pan-Asian; guidelines; metastatic colorectal cancer; treatment | 公開日期: | 24-五月-2023 | 卷: | 8 | 期: | 3 | 來源出版物: | ESMO open | 摘要: | The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633126 | ISSN: | 20597029 | DOI: | 10.1016/j.esmoop.2023.101558 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。